immutep (asx:imm) reports positive trial data
Published 4 years ago • 379 plays • Length 3:33Download video MP4
Download video MP3
Similar videos
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
6:03
immutep (asx:imm) reports positive discussions with the fda and strong survival data
-
5:10
immutep (asx:imm) reports first subject dosed in autoimmune disease study
-
16:06
immutep (asx:imm) - webinar presentation
-
7:17
immutep (asx:imm) delivering strong data in first-line non-small cell lung cancer
-
5:07
immutep (asx:imm) clinical trial program milestones
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
5:10
immutep (asx:imm) reports first subject dosed in autoimmune disease study
-
18:36
biotech unlocked - imugene asx:imu
-
16:07
immutep (asx:imm) - webinar presentation
-
7:09
immutep (asx:imm) reports 71.4% response rate for lung cancer therapy
-
4:19
immutep (asx:imm) clinical trial update
-
4:06
immutep (asx:imm) 1h19 results and outlook
-
16:07
immutep (asx:imm) - webinar presentation
-
5:17
immutep (asx:imm) clinical trial update and partnerships
-
52:08
immutep (asx:imm) - update on tacti-002 phase ii and insight-003 phase 1 data presented at sitc 2022
-
4:54
immutep (asx:imm) 1h20 results & outlook
-
4:40
immutep (asx:imm) announces encouraging trial data for lung cancer therapy
-
15:49
immutep (asx:imm) - webinar presentation
-
5:20
immutep (asx:imm) fy18 results
-
56:38
immutep (asx:imm) webcast for tacti-002 data presented at asco 2022
-
31:08
immutep (asx:imm) 2023 agm - ceo presentation